Clinical application of genetically modified T cells in cancer therapy. Issue 5 (16th May 2014)

• Record Type: Journal Article
• Authors: Kershaw, Michael H; Westwood, Jennifer A; Slaney, Clare Y; Darcy, Phillip K
• Is Part Of: Clinical & translational immunology. Volume 3:Issue 5 (2014)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2014-05-16
• Subjects: adoptive cell transfer -- chimeric antigen receptor -- gene therapy; Immunologic diseases -- Periodicals; Immunology -- Periodicals; Clinical medicine -- Periodicals; Immune System Diseases -- therapy; Immunotherapy; Immunologic Factors -- therapeutic use; Translational Medical Research; Molecular Targeted Therapy; Clinical medicine; Immunologic diseases; Immunology; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.079
• DOI: 10.1038/cti.2014.7
• Languages: English
• ISSNs: 2050-0068

Abstract

Abstract : Immunotherapies are emerging as highly promising approaches for the treatment of cancer. In these approaches, a variety of materials are used to boost immunity against malignant cells. A key component of many of these approaches is functional tumor‐specific T cells, but the existence and activity of sufficient T cells in the immune repertoire is not always the case. Recent methods of generating tumor‐specific T cells include the genetic modification of patient lymphocytes with receptors to endow them with tumor specificity. These T cells are then expanded in vitro followed by infusion of the patient in adoptive cell transfer protocols. Genes used to modify T cells include those encoding T‐cell receptors and chimeric antigen receptors. In this review, we provide an introduction to the field of genetic engineering of T cells followed by details of their use against cancer in the clinic.